We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+2.9%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.56B
AUM Growth
-$71.2M
Cap. Flow
-$99.6M
Cap. Flow %
-3.9%
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
27
Reduced
32
Closed
20

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$20M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.2M
3
AMGN icon
Amgen
AMGN
+$14.1M
4
PODD icon
Insulet
PODD
+$13.3M
5
BAX icon
Baxter International
BAX
+$11.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$31.7M
2
CI icon
Cigna
CI
+$22.5M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$22.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$13.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.28%
2 Real Estate 2.09%
3 Miscellaneous 1.37%
4 Industrials 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADPT icon
101
Adaptive Biotechnologies
ADPT
$4.26B
$2.83M 0.11%
422,281
– –
GRTX
102
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$2.8M 0.11%
898,374
– –
XENE icon
103
Xenon Pharmaceuticals
XENE
$5.45B
$2.6M 0.1%
67,506
-16,208
-19% -$644K
BBIO icon
104
BridgeBio Pharma
BBIO
$13.4B
$2.6M 0.1%
150,921
– –
PHG icon
105
Philips
PHG
$24.3B
$2.49M 0.1%
128,301
-1
-0% -$17
CRBU icon
106
Caribou Biosciences
CRBU
$136M
$2.41M 0.09%
567,147
– –
MRTX
107
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.37M 0.09%
65,490
– –
ICLR icon
108
Icon
ICLR
$13.3B
$2.34M 0.09%
9,334
– –
AMLX icon
109
Amylyx Pharmaceuticals
AMLX
$3.69B
$2.24M 0.09%
+104,007
New +$2.81M
ASRT
110
DELISTED
Assertio
ASRT
$2.23M 0.09%
27,372
– –
MREO
111
Mereo BioPharma
MREO
$45.5M
$2.05M 0.08%
1,551,082
– –
ETNB
112
DELISTED
89bio
ETNB
$2.01M 0.08%
105,898
– –
ARDX icon
113
Ardelyx
ARDX
$878M
$1.83M 0.07%
539,408
– –
PYXS icon
114
Pyxis Oncology
PYXS
$278M
$1.81M 0.07%
708,303
– –
PRGO icon
115
Perrigo
PRGO
$1.88B
$1.74M 0.07%
51,224
– –
TAK icon
116
Takeda Pharmaceutical
TAK
$59.7B
$1.65M 0.06%
105,073
– –
XRN
117
Chiron Real Estate Inc
XRN
$478M
$1.6M 0.06%
34,979
– –
GSK icon
118
GSK
GSK
$100B
$1.49M 0.06%
41,852
– –
TCMD icon
119
Tactile Systems Technology
TCMD
$510M
$1.46M 0.06%
58,472
+24,040
+70% +$499K
ARQT icon
120
Arcutis Biotherapeutics
ARQT
$2.96B
$1.42M 0.06%
148,874
– –
XNCR icon
121
Xencor
XNCR
$1.77B
$1.42M 0.06%
+56,675
New +$1.54M
CRNX
122
DELISTED
Crinetics Pharmaceuticals
CRNX
$1.42M 0.06%
78,529
– –
MOR
123
DELISTED
MorphoSys AG American Depositary Shares
MOR
$1.32M 0.05%
177,191
+95,324
+116% +$580K
CRSP icon
124
CRISPR Therapeutics
CRSP
$5.01B
$1.27M 0.05%
22,571
-32,509
-59% -$1.84M
NTRA icon
125
Natera
NTRA
$50.6B
$1.2M 0.05%
24,636
-24,636
-50% -$1.26M
3 4
5
6 7

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Tekla Capital Management held 186 positions worth $2.56B, down 2.7% from $2.63B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management withdrew a net $99.6M in Q2 2023, closing 20 positions and reducing 32 holdings. Its most notable exit was Travere Therapeutics, an estimated $9.41M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Miscellaneous.

Against the trend, Tekla Capital Management opened a new position in Insulet worth $12.6M.

  • Tekla Capital Management's largest Q2 2023 buy was Insulet: 43,847 shares worth $12.6M.
  • Tekla Capital Management added most to Merck in Q2 2023, an estimated $20M increase.
  • Tekla Capital Management's biggest Q2 2023 reduction was Eli Lilly, cutting an estimated $31.7M.
  • Tekla Capital Management fully exited Travere Therapeutics in Q2 2023, selling an estimated $9.41M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.56B portfolio in Q2 2023.
  • Tekla Capital Management opened 9 new positions and closed 20 in Q2 2023.
  • Tekla Capital Management's portfolio value fell 2.7% quarter-over-quarter to $2.56B.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.